A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

ClinicalTrials.gov ID: NCT00002424

Public ClinicalTrials.gov record NCT00002424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized Pilot Study to Compare the Safety and Activity of L-756423/Indinavir, 1600/800 Mg Qd or 800/400 Mg Bid Versus Indinavir, 800 Mg q8h, All in Combination With Stavudine and Lamivudine

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC). The study will also see whether taking 1 large dose of L-756423/IDV once a day is as safe and effective as taking 2 smaller doses twice a day.

Study identification

NCT ID: NCT00002424
Recruitment status: Suspended
Study type: Interventional
Phase: Phase 2
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Enrollment: 186 participants

Conditions and interventions

Conditions

HIV Infections

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: Jun 23, 2005

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
UCLA School of Medicine / Ctr for Research and Education	Los Angeles	California	900951793	—
Georgetown Univ Med Ctr	Washington D.C.	District of Columbia	20007	—
ViRx / Dupont Circle Physicians Group	Washington D.C.	District of Columbia	20009	—
Associates in Research	Fort Myers	Florida	33901	—
Univ of Miami School of Medicine	Miami	Florida	33136	—
Grady Mem Hosp	Atlanta	Georgia	30308	—
Rush Presbyterian - Saint Luke's Med Ctr	Chicago	Illinois	60612	—
The CORE Ctr	Chicago	Illinois	60612	—
Univ of Kentucky Med Ctr	Lexington	Kentucky	40536	—
Univ of Kentucky	Lexington	Kentucky	40536	—
Beth Israel Deaconess Med Ctr	Boston	Massachusetts	02215	—
Henry Ford Hosp	Detroit	Michigan	48202	—
NYU Med Ctr / C & D Building	New York	New York	10016	—
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ	New York	New York	10021	—
SUNY at Stony Brook / Div of Infectious Disease	Stony Brook	New York	117948153	—
The Miriam Hosp	Providence	Rhode Island	02906	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00002424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2005 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002424 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →